1. Biological and Molecular Effects of Small Molecule Kinase Inhibitors on Low-Passage Human Colorectal Cancer Cell Lines
   Falko Lange et al, 2014, BioMed Research International CrossRef
2. Multiparametric Analysis of Oncology Drug Screening with Aqueous Two-Phase Tumor Spheroids
   Pradip Shahi Thakuri et al, 2016, Mol. Pharmaceutics CrossRef
3. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer
   Woo-Jeong Jeong, 2014, WJG CrossRef
4. Myeloid-Derived Suppressor Cells as a Regulator of Immunity in Organ Transplantation
   Tsukasa Nakamura et al, 2018, IJMS CrossRef
5. Study of Molecular Mechanism of the Interaction Between MEK1/2 and Trametinib with Docking and Molecular Dynamic Simulation
   Sh. Hashemzadeh et al, 2018, Interdiscip Sci Comput Life Sci CrossRef
6. Transforming growth factor-β downregulates sGC subunit expression in pulmonary artery smooth muscle cells via MEK and ERK signaling
   Lili Du et al, 2019, American Journal of Physiology-Lung Cellular and Molecular Physiology CrossRef
7. Cell lines of human melanoma and their xenograft with braf or nras mutations a targets for targeted therapy. Reviews
   I. N. Mikhaylova et al, 2019, Rossijskij bioterapevtičeskij žurnal CrossRef
8. Capsaicin Induces Apoptosis in KSHV-Positive Primary Effusion Lymphoma by Suppressing ERK and p38 MAPK Signaling and IL-6 Expression
   Misato Moriguchi et al, 2019, Front. Oncol. CrossRef
9. Synergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors
   Xuguang Zhu et al, 2018, Oncotarget CrossRef
10. Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia.
    Anouchka P Laurent et al, 2020, Clin Cancer Res CrossRef
11. Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
    Christina Wu et al, 2020, Clin Cancer Res CrossRef
12. Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells
    Kyu Sic You et al, 2021, Cancers CrossRef
13. Oncogenic FGFR Fusions Produce Centrosome and Cilia Defects by Ectopic Signaling
    Alexandru Nita et al, 2021, Cells CrossRef
14. Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer
    Kyu Sic You et al, 2021, Pharmaceuticals CrossRef
15. Allosteric MEK inhibitors act on BRAF/MEK complexes to block MEK activation
    Gonzalo L. Gonzalez-Del Pino et al, 2021, Proc Natl Acad Sci USA CrossRef
16. Ribosomal Protein S6: A Potential Therapeutic Target against Cancer?
    Yong Weon Yi et al, 2021, IJMS CrossRef
17. Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: A Case Report
    Ziyao Wang et al, 2022, Front. Oncol. CrossRef
18. BRAF and MEK Targeted Therapies in Pediatric Central Nervous System Tumors
    Dario Talloa et al, 2022, Cancers CrossRef
19. Kinase-Modulated Bioluminescent Indicators Enable Noninvasive Imaging of Drug Activity in the Brain
    Yan Wu et al, 2023, ACS Cent. Sci. CrossRef
20. A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System Events for Trametinib
    Xinyue Zhang et al, 2024 CrossRef
21. Functional genomics pipeline identifies CRL4 inhibition for the treatment of ovarian cancer
    Sally E. Claridge et al, 2025, Clinical & Translational Med CrossRef